Details of the Drug

General Information of Drug (ID: DMFA5MY)

Drug Name

Metoclopramide

Synonyms

Cerucal; Clopra; Clopromate; Duraclamid; Elieten; Emetid; Emitasol; Emperal; Eucil; Gastrese; Gastrobid; Gastromax; Gastronerton; Gastrosil; Gastrotablinen; Gastrotem; Imperan; Maxeran; Maxolon; Meclopran; Metaclopramide; Metaclopromide; Metamide; Methochlopramide; Methoclopramide; Metochlopramide; Metoclol; Metoclopramida; Metoclopramidum; Metocobil; Metramid; Moriperan; Mygdalon; Octamide; Parmid; Paspertin; Peraprin; Plasil; Pramidin; Pramiel; Pramin; Primperan; Reclomide; Reglan; Reliveran; Terperan; Metoclopramide Omega; DEL 1267; Apo-Metoclop; CLOPRA-YELLOW; Clopra-Yellow; Degan (TN); Elieten (TN); Gastro-Timelets; Maxeran (TN); Maxolon (TN); Metoclopramida [INN-Spanish]; Metoclopramide Monohydrochloride, Monohydrate; Metoclopramidum [INN-Latin]; Neu-Sensamide; Nu-Metoclopramide; Plasil (pharmaceutical); Pms-Metoclopramide; Primperan (TN); Pylomid (TN); Reglan (TN); Terperan (TN); Metoclopramide (JP15/INN); Metoclopramide [INN:BAN:JAN]; N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide; O-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-(8CI); Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-(9CI); (metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; (metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 1,5-Dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one; 2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide; 2-Methoxy-5-chloroprocainamide; 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide; 4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide); 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide; 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide; 5-Chloro-2-methoxyprocainamide

Indication

Disease Entry	ICD 11	Status	REF
Nausea	MD90	Approved	[1], [2]

Therapeutic Class

Antiemetics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

299.79

Topological Polar Surface Area (xlogp)

2.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 367 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 41.0 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.25 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 40.7% [3]
Clearance: The renal clearance of drug is 0.16 L/h/kg [3]
Elimination: About 85% of an orally administered dose was measured in the urine within 72 hours during a pharmacokinetic study [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 5 - 6 hours [3]
Metabolism: The drug is metabolized via the cytochrome P450 enzymes in the liver [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 33.3556 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.6% [8]
Vd: The volume of distribution (Vd) of drug is 3.5 L/kg [9]
Water Solubility: The ability of drug to dissolve in water is measured as 0.2 mg/mL [4]

Chemical Identifiers

Formula: C14H22ClN3O2
IUPAC Name: 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
Canonical SMILES: CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl
InChI: InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
InChIKey: TTWJBBZEZQICBI-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4168
ChEBI ID: CHEBI:107736
CAS Number: 364-62-5
DrugBank ID: DB01233
TTD ID: D08VYV
VARIDT ID: DR00840
INTEDE ID: DR1068
ACDINA ID: D00422

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[10], [11]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[13]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[13]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Nausea

ICD Disease Classification

MD90

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Organic cation transporter 1 (SLC22A1)	DTP	SLC22A1	8.54E-01	1.24E-02	7.20E-02
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.36E-01	1.62E-02	1.08E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Metoclopramide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Metoclopramide caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[60]
-----------

Coadministration of a Drug Treating the Disease Different from Metoclopramide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Moderate	Additive hypertensive effects by the combination of Metoclopramide and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[61]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Metoclopramide caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[62]
Posaconazole	DMUL5EW	Moderate	Altered absorption of Metoclopramide due to GI dynamics variation caused by Posaconazole.	Aspergillosis [1F20]	[63]
Cariprazine	DMJYDVK	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Cariprazine.	Bipolar disorder [6A60]	[64]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Metoclopramide and Dihydrocodeine.	Chronic pain [MG30]	[65]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Metoclopramide and Atracurium.	Corneal disease [9A76-9A78]	[66]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Metoclopramide and Pancuronium.	Corneal disease [9A76-9A78]	[66]
Isocarboxazid	DMAF1NB	Moderate	Additive hypertensive effects by the combination of Metoclopramide and Isocarboxazid.	Depression [6A70-6A7Z]	[61]
OPC-34712	DMHG57U	Major	Additive antidopaminergic effects by the combination of Metoclopramide and OPC-34712.	Depression [6A70-6A7Z]	[64]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Metoclopramide and Esketamine.	Depression [6A70-6A7Z]	[67]
Mepenzolate	DM8YU2F	Moderate	Antagonize the effect of Metoclopramide when combined with Mepenzolate.	Digestive system disease [DE2Z]	[68]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[64]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Deutetrabenazine.	Dystonic disorder [8A02]	[64]
Solifenacin	DMG592Q	Moderate	Antagonize the effect of Metoclopramide when combined with Solifenacin.	Functional bladder disorder [GC50]	[68]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Metoclopramide caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[69]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Metoclopramide caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[70]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Metoclopramide caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[71]
Belladonna	DM2RBWK	Moderate	Antagonize the effect of Metoclopramide when combined with Belladonna.	Infectious gastroenteritis/colitis [1A40]	[68]
ITI-007	DMUQ1DO	Major	Additive antidopaminergic effects by the combination of Metoclopramide and ITI-007.	Insomnia [7A00-7A0Z]	[64]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Metoclopramide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[72]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Metoclopramide caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[73]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Metoclopramide caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[74]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Metoclopramide caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[75]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Metoclopramide and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[76]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Metoclopramide and Lasmiditan.	Migraine [8A80]	[77]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Metoclopramide and Flibanserin.	Mood disorder [6A60-6E23]	[78]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Metoclopramide caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[79]
Ozanimod	DMT6AM2	Moderate	Increased risk of hyperpyrexia by the combination of Metoclopramide and Ozanimod.	Multiple sclerosis [8A40]	[61]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Metoclopramide caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[73]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Metoclopramide caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[80]
Lorcaserin	DMG6OYJ	Moderate	Increased risk of hyperprolactinemic effects by the combination of Metoclopramide and Lorcaserin.	Obesity [5B80-5B81]	[81]
Safinamide	DM0YWJC	Moderate	Additive hypertensive effects by the combination of Metoclopramide and Safinamide.	Parkinsonism [8A00]	[61]
Opicapone	DM1BKA6	Moderate	Additive CNS depression effects by the combination of Metoclopramide and Opicapone.	Parkinsonism [8A00]	[82]
Rasagiline	DM3WKQ4	Moderate	Increased risk of hyperpyrexia by the combination of Metoclopramide and Rasagiline.	Parkinsonism [8A00]	[61]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Metoclopramide when combined with Levodopa.	Parkinsonism [8A00]	[82]
Methylscopolamine	DM5VWOB	Moderate	Antagonize the effect of Metoclopramide when combined with Methylscopolamine.	Peptic ulcer [DA61]	[68]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Metoclopramide caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[83]
Levomepromazine	DMIKFEL	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[64]
Neupro	DMHEAB1	Moderate	Additive CNS depression effects by the combination of Metoclopramide and Neupro.	Restless legs syndrome [7A80]	[82]
Aripiprazole	DM3NUMH	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Aripiprazole.	Schizophrenia [6A20]	[64]
Iloperidone	DM6AUFY	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Iloperidone.	Schizophrenia [6A20]	[64]
Paliperidone	DM7NPJS	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Paliperidone.	Schizophrenia [6A20]	[64]
Molindone	DMAH70G	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Molindone.	Schizophrenia [6A20]	[64]
Thiothixene	DMDINC4	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Thiothixene.	Schizophrenia [6A20]	[64]
Amisulpride	DMSJVAM	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Amisulpride.	Schizophrenia [6A20]	[64]
Asenapine	DMSQZE2	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Asenapine.	Schizophrenia [6A20]	[64]
Pitolisant	DM8RFNJ	Moderate	Decreased metabolism of Metoclopramide caused by Pitolisant mediated inhibition of CYP450 enzyme.	Somnolence [MG42]	[73]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Metoclopramide and Vecuronium.	Tonus and reflex abnormality [MB47]	[66]
Trimeprazine	DMEMV9D	Major	Additive antidopaminergic effects by the combination of Metoclopramide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[84]
-----------


⏷ Show the Full List of 49 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acesulfame	E00341	36573	Flavoring agent
Aspartame	E00402	134601	Flavoring agent
Butylated hydroxytoluene	E00336	31404	Antioxidant
FD&C blue no. 1	E00263	19700	Colorant
Hydrochloric acid	E00015	313	Acidulant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Phosphoric acid	E00039	1004	Acidulant; Buffering agent
Quinoline yellow WS	E00309	24671	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Calcium hydrogenphosphate	E00294	24441	Diluent
Crospovidone	E00626	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Metoclopramide 10 mg tablet	10 mg	Disintegrating Oral Tablet	Oral
Metoclopramide 5 mg tablet	5 mg	Disintegrating Oral Tablet	Oral
Metoclopramide 10 mg tablet	10 mg	Oral Tablet	Oral
Metoclopramide 5 mg tablet	5 mg	Oral Tablet	Oral
Metoclopramide Hydrochloride eq 5mg base/ml injectable	eq 5mg base/ml	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 241).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070184.
3	Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet. 1983 Nov-Dec;8(6):523-9. doi: 10.2165/00003088-198308060-00003.
4	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
5	Metoclopramide FDA label
6	Jiang G, Zhang BB: Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E671-8.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9	Ross-Lee LM, Eadie MJ, Hooper WD, Bochner F: Single-dose pharmacokinetics of metoclopramide. Eur J Clin Pharmacol. 1981;20(6):465-71. doi: 10.1007/bf00542101.
10	Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats. Eur J Pharmacol. 2008 Jun 10;587(1-3):181-6.
11	The significance of disordered gastric emptying. Z Gastroenterol. 1986 Sep;24 Suppl 2:45-54.
12	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
13	Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
14	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
24	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
25	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
26	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
27	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
28	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
29	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
30	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
31	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
32	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
33	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
34	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
35	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
36	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
37	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
38	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
39	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
40	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
41	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
42	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
43	Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
44	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
45	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
46	Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
47	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
48	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
49	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
50	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
51	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
52	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
53	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
54	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
55	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
56	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
57	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
58	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
59	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
60	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
61	Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984): 548-9. [PMID: 6541544]
62	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
63	Product Information. Noxafil (posaconazole). Schering-Plough Corporation, Kenilworth, NJ.
64	Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
65	Manara AR, Shelly MP, Quinn K, Park GR "The effect of metoclopramide on the absorption of oral controlled release morphine." Br J Clin Pharmacol 25 (1988): 518-21. [PMID: 3382595]
66	Multum Information Services, Inc. Expert Review Panel.
67	Cerner Multum, Inc. "Australian Product Information.".
68	Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
69	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
70	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
71	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
72	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
73	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
74	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
75	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
76	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
77	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
78	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
79	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
80	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
81	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
82	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
83	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
84	Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993): 1469-75. [PMID: 8512437]